ABC	advanced breast cancer
ADC	antibody-drug-conjugates
AE	adverse event
AF-HPA	auristatin f-hydroxypropylamide
ALT	alanine transaminase
AST	aspartate transaminase
CBR	clinical benefit rate
CI	confidence interval
CR	complete response
DAR	drug antibody ratio
DCR	disease control rate
DFS	disease-free survival
DOR	duration of response
EGF	epidermal growth factor
EGFR	epidermal growth factor receptor
HER2	human epidermal growth factor receptor 2
HER3	human epidermal growth factor receptor 3
HER4	human epidermal growth factor receptor 4
ISH	in situ hybridization
IHC	immunohistochemistry
ILD	interstitial lung disease
MBC	metastatic breast cancer
MDT	maximum tolerated dose
MMAE	monomethyl auristatin E
MMAF	monomethyl auristatin F
ORR	overall response rate
PFS	progression-free survival
PBD-MA	pyrrolo[2,1-c][1,4]benzodiazepine monoamide
PR	partial response
Q2W	every 2 weeks
Q3W	every 3 weeks
ROR2	receptor tyrosine kinase-like orphan receptor 2
RP2D	recommended phase 2 dose
SAE	serious adverse event
SD	stable disease